Prosecution Insights
Prosecution Insights
2 pending office actions • 0 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Ningbo T-Maximum Biopharmaceuticals Co. Ltd. currently has 2 pending office actions. These actions are distributed between 2 distinct examiners, meaning each examiner is responsible for a single matter.
Elly Gerald Stoica is the busiest examiner, managing 1 pending office action. With 2 pending office actions and 2 distinct examiners, the workload is evenly split. The 0 distinct art units listed for this profile indicate a specific administrative status for these 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
| STOICA, ELLY GERALD | 1 | 66.9% | +22.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18575451 | UNIVERSAL CAR-T CELL TARGETING GD2, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | STOICA, ELLY GERALD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18575628 | UNIVERSAL CAR-T CELL TARGETING IL13RALPHA2, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | OUSPENSKI, ILIA I | — |
| 18575451 | UNIVERSAL CAR-T CELL TARGETING GD2, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | STOICA, ELLY GERALD | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18575628 | UNIVERSAL CAR-T CELL TARGETING IL13RALPHA2, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | OUSPENSKI, ILIA I | — | §103§112DP | Non-Final OA | — | Pending | Dec 29, 2023 |
| 18575451 | UNIVERSAL CAR-T CELL TARGETING GD2, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | STOICA, ELLY GERALD | — | §102§103 | Non-Final OA | — | Pending | Dec 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial